Significant FDA Enforcement Developments: Challenges and Opportunities
FDA’s enforcement landscape continues to evolve as the agency implements its new legislative authorities, advances its regulation of cutting-edge issues, addresses significant supply chain concerns, and deals with the fallout from the COVID-19 public health emergency. Despite the evolving landscape, enforcement related to manufacturing and data integrity-related deficiencies and unapproved new products remain at the core of the agency’s enforcement priorities.